The Prescription Shadow Market: How Healthcare Middlemen Inflate Your Medicine
I. The Structural Flaw in Prescription Drug Pricing
When purchasing a prescription medication, the consumer price is rarely a reflection of manufacturing costs plus a standard retail markup. Instead, the final price is determined by intermediaries known as Pharmacy Benefit Managers (PBMs), which operate between drug manufacturers, health insurers, and pharmacies. Originally designed to handle administrative tasks and negotiate lower drug prices for insurance plans, PBMs have evolved into heavily consolidated corporate entities. The market is now dominated by the "Big 3"—Caremark Rx, Express Scripts, and OptumRx—which together administered approximately 80% of U.S. prescriptions in 2023. Their business models rely on complex revenue streams that fundamentally disconnect a drug's list price from its actual net cost, artificially inflating expenses for patients whose out-of-pocket payments are tied to those high list prices.
II. The Mechanics of Rebates and Formulary Placement
One of the primary mechanisms driving up drug costs is the rebate system. PBMs negotiate rebates from drug manufacturers in exchange for placing those drugs in favorable tiers on an insurer's formulary list, which dictates what drugs the insurance plan covers. Because these manufacturer rebates are calculated as a percentage of the drug's initial list price, PBMs are financially incentivized to favor higher-priced medications. This dynamic encourages manufacturers to continually raise their list prices so they can offer larger rebates to secure favorable formulary placement.
While a portion of these rebates may be passed on to insurers to lower overall premiums, PBMs frequently retain a significant percentage of the rebates as revenue. The Federal Trade Commission (FTC) has alleged that this rebate-driven structure explicitly prioritizes high rebates over lower costs, leading to artificially inflated list prices for critical drugs like insulin. Because a patient's coinsurance or deductible payment at the pharmacy counter is often based on the inflated list price rather than the discounted net price, the patient absorbs the financial burden of this rebate system.
III. Spread Pricing: Profiting off the Margins
Beyond manufacturer rebates, PBMs generate substantial revenue through a practice known as "spread pricing". In this model, a PBM reimburses a retail pharmacy a specific amount for dispensing a medication, but then charges the health insurance plan (or a government program like Medicaid) a significantly higher amount for that same claim. The PBM keeps the difference—the "spread"—as profit.
The financial impact of spread pricing is massive. For example, an audit in Ohio revealed that PBMs pocketed $224.8 million through the spread alone in just a single year on Medicaid prescription drugs. Additionally, the FTC found that between 2017 and 2022, the Big 3 PBMs generated an estimated $1.4 billion in income specifically from spread pricing on specialty generic drugs.
IV. Vertical Integration and Unprecedented Markups
The market power of the Big 3 PBMs is amplified by vertical integration; they do not just manage benefits, they also own and operate their own mail-order and specialty pharmacies. By steering patients to their own affiliated pharmacies, PBMs can impose massive, opaque markups.
The financial impact of this vertical integration is staggering. Between 2017 and 2022, the Big 3 PBMs and their affiliated pharmacies generated more than $7.3 billion in revenue strictly above the estimated acquisition costs of specialty generic drugs. This was not a stagnant revenue stream; dispensing revenue from these excessive markups experienced an explosive compound annual growth rate of 42% from 2017 to 2021. The concentration of this profit is equally alarming, as the top 10 specialty generic drugs alone accounted for over $6.2 billion of the dispensing revenue generated above their acquisition costs.
V. The Bipartisan Push for Accountability
The push to regulate PBMs has become a rare area of bipartisan consensus in Washington, as lawmakers from both parties recognize the need to eliminate hidden healthcare fees and lower drug costs.
Regulatory agencies have taken aggressive action against these monopolistic practices. In February 2026, the FTC secured a landmark settlement with Express Scripts requiring fundamental business changes intended to save patients up to $7 billion over ten years. Following this precedent, in July 2026, the FTC secured another major settlement with Caremark Rx. This agreement requires Caremark to adopt structural changes to drive down patient costs, increase transparency, pass through rebates at the point of sale, and ensure fair treatment for community pharmacies. At the federal legislative level, the 2026 Consolidated Appropriations Act (H.R. 7148) further solidifies this momentum by reforming PBM compensation structures and increasing reporting requirements.
VI. A Centrist Market Solution: Mandating Transparency
Addressing the inflated cost of American healthcare does not strictly require choosing between a single-payer system or a completely deregulated free market. A centrist approach focuses on the fundamental prerequisite of any functioning market: price transparency.
The current system relies on opaque practices, hidden rebates, and undisclosed spreads to generate revenue for intermediaries. Instead of arguing over systemic overhauls like a transition away from the Patient Protection and Affordable Care Act, we should demand complete, upfront price transparency. By requiring PBMs to disclose the true net cost of a drug, pass 100% of rebates directly to the point of sale, and explicitly detail all administrative fees, the market can organically drive down costs. When employers, insurers, and patients can clearly see the financial flow among all entities in the drug supply chain, competition is restored, forcing middlemen to provide genuine value rather than exploiting hidden margins.
This article is an opinion-based editorial. It reflects the analysis and views of the author, G. Moraga, and does not constitute independent news reporting.
